Differential Effects of Interleukin-6 and -10 on Skeletal Muscle and Liver Insulin Action In Vivo

Diabetes

Volumn 53, Issue 4, 2004, Pages 1060-1067

  Kim, Hyo Jeong ^a   Higashimori, Takamasa ^a   Park, So Young ^a   Choi, Hyejeong ^a   Dong, Jianying ^a   Kim, Yoon Jung ^a   Noh, Hye Lim ^a   Cho, You Ree ^a   Cline, Gary ^a   Kim, Young Bum ^b   Kim, Jason K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 10; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIV ASSOCIATED LIPODYSTROPHY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; INSULIN RESPONSE; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; BLOOD GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; INFUSIONS, INTRAVENOUS; INSULIN; INTERLEUKIN-10; INTERLEUKIN-6; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION;

EID: 12144290761     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.4.1060     Document Type: Article

References (57)

1. Kahn CR: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084, 1994
2. DeFronzo RA: The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667-687, 1988
3. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
4. Boden G: Obesity, free fatty acids, and insulin resistance. Curr Opin Endocr Diabetes 8:235-239, 2001
5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998
6. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275:20251-20254, 2000
7. Fogar P, Basso D, Pasquali C, Piva MG, Brigato L, De Paoli M, Galeotti F, Corsini A, Plebani M: Portal but not peripheral serum levels of interleukin-6 could interfere with glucose metabolism in patients with pancreatic cancer. Clin Chim Acta 277:181-189, 1998
8. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001
9. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
10. Kahn CR, Chen L, Cohen SE: Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106:1305-1307, 2000
11. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
12. Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJM, Veenhof CHN, Sauerwein HP: Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 268:E813-E819, 1995
13. Pickup JC, Chusney GD, Thomas SM, Burt D: Plasma interleukin-6, tumor necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 67:291-300, 2000
14. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol 280:E745-E751, 2001
15. Kishimoto T: The biology of interleukin-6. Blood 71:1-10, 1989
16. Greenberg AS, McDaniel ML: Identifying the links between obesity, insulin resistance, and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32:24-34, 2002
17. Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399, 2002
18. Stouthard JM, Oude Elferink RPJ, Sauerwein HP: Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biopys Res Comm 220:241-245, 1996
19. Pedersen BK, Steensberg A, Schjerling P: Exercise and interleukin-6. Curr Opin Hematol 8:137-141, 2001
20. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W: Interlekin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520, 2000
21. Vozarova B, Fernandez-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK: The interleukin-6(-174) G/C promotor polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112: 409-413, 2003
22. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246, 1999
23. Kim JK, Kim Y-J, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437-446, 2001
24. Yin M-J, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396:77-80, 1998
25. Schottelius AJG, Mayo MW, Sartor RB, Baldwin AS: Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 274:31868-31874, 1999
26. Van Exel E, Gussekloo J, De Craen AJ, Frolich M, Bootsnia-Van Der Wiel A, Westendorp RG: Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 51:1088-1092, 2002
27. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, Shulman GI: Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 105:1791-1797, 2000
28. Kim YB, Shulman GI, Kahn BB: Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C λ/ζ but not on glycogen synthase kinase-3. J Biol Chem 277:32915-32922, 2002
29. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917, 1959
30. Sandler S, Bendtzen K, Eizirik DL, Welsh M: Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 126:1288-1294, 1990
31. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K, Hellerstrom C: Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest 93:1968-1974, 1994
32. Stith RD, Luo J: Endocrine and carbohydrate response to interleukin-6 in vivo. Circ Shock 44:210-215, 1994
33. Previs SF, Withers DJ, Ren J-M, White MF, Shulman GI: Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 275:38990-38994, 2000
34. Ritchie DG: Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools. Am J Physiol 258:E57-E64, 1990
35. Kanemaki T, Kitade H, Kaibori M, Sakitani K, Hiramatsu Y, Kamiyama Y, Ito S, Okumura T: Interleukin 1β and interleukin 6, but not tumor necrosis factor α, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27:1296-1303, 1998
36. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson J-O: Interleukin-6 deficient mice develop mature-onset obesity. Nat Med 8:75-79, 2002
37. Baron AD, Brechtel G, Wallace P, Edelman SV: Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 255:E769-E774, 1988
38. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T: Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263:89-92, 1994
39. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63-71, 1994
40. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T: Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J 15:1557-1565, 1996
41. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine-signaling-3 (SCOS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746, 2003
42. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E: SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985-15991, 2000
43. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Obberghen EV: SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice. J Biol Chem 276:47944-47949, 2001
44. Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394-42398, 2002
45. Zhang Y, Pilon G, Marette A, Baracos VE: Cytokines and endotoxin induce cytokine receptors in skeletal muscle. Am J Physiol 279:E196-E205, 2000
46. Boden G, Lebed B, Schatz M, Homko C, Lemieux S: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612-1617, 2001
47. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98:7522-7527, 2001
48. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic patients. Diabetes 48:1600-1606, 1999
49. Bjorntorp P: Obesity. Lancet 350:423-426, 1997
50. Shulman GI: Cellular mechanisms of insulin resistance: J Clin Invest 106:171-176, 2000
51. Itani SI, Zhou Q, Pories WJ, MacDonald KG, Dohm GL: Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 49:1353-1368, 2000
52. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKK-beta. Science 293:1673-1677, 2001
53. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
54. Chalkley SM, Hettiarachchi M, Chisholm DJ, Kraegen EW: Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 47:1121-1126, 1998
55. 307 via distinct pathways. J Clin Invest 107:181-189, 2001
56. Pederson TM, Kramer DL, Rondinone CM: Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50:24-31, 2001
57. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated PI 3-kinase activity in muscle. J Biol Chem 277:50230-50236, 2002